INTRODUCTION: A meta-analysis of 34 studies estimated that the risk was increased by almost 70 percent in HCV-infected patients compared with non-infected controls. Insulin resistance has been hypothesized to develop via a multimodal pathway. The virus itself causes this through serine and threonine phosphorylation of insulin receptor substrate-1. Hepatitis creates a ubiquitous inflammatory state by releasing proinflammatory cytokines such as interleukin-6 and tumor necrosis factor-α, which upregulates gluconeogenesis. We aimed to analyze the unique patient population cared for at Louisiana State University diagnosed with DM2 and HCV who have completed direct-acting antiviral treatment with a sustained viral response (SVR). We attempted to establish a connection between a SVR and improved glycemic control and quantify the variations in HbA1C. METHODS: Using ICD 9/10/CPT codes the study included all patients with DM2 who underwent HCV treatment with DAA. SVR was achieved in all patients using non-ribavirin and non-interferon based therapies. SVR was defined as viral load below the lower limit of quantification after the completion of treatment. Treatments varied between 8 weeks and 12 weeks. We further divded the patient population into two groups and statistically analyzed patients with Severe Fibrosis/Cirrhosis to those without. Comparative analysis and Fisher’s exact test was performed. RESULTS: The F-test for increase in Metavir score correlated with a mean drop of 0.5% in HbA1c gives a P Value of 0.01652. DM2 Pts who achieved SVR had an overal drop in HbA1C of 0.39 (P = 0.009), while Cirrhotics experieces the largest median decrease 0.65% (P = 0.004). SF/Cirrhotic patients experienced the largest drop in median Isulin requirements post-treatment, decrease of 6.32 Units (P = .206). SF/Cirrhotic patients also experienced the largest median decrease in number of classes of anti-diabetic medications (P = .445). CONCLUSION: Analysis revealed statistically signficant results in regards to reduction in HbA1C, with the greatest benefits experiened by the SF/Cirrhotic cohort.The improvement in microvascular complications in diabetics with a reduction in HbA1C has been confirmed by multiple studies. An increase in the number of investigations with similar findings can assist insurance companies in completing a risk benefit analysis in providing full treatment compensation to all HCV patients with concomitant DM2.